Lobbying client
BELLEROPHON THERAPEUTICS
Clinical-stage biotherapeutics company.
Filings
5
Filed by
1
Reported in-house
—
Reported by firms
$170,000
Reported lobbying by year
The larger of in-house and firm-reported each year, $ thousands
2020 to 2021
Filings
5 filings, newest first.
| Filing | Filed by | Amount |
|---|---|---|
|
1st Quarter - Termination (No Activity) 1st Quarter 2021
|
FORBES-TATE | — reported |
|
4th Quarter - Report 4th Quarter 2020
|
FORBES-TATE | $30,000 reported |
|
3rd Quarter - Report 3rd Quarter 2020
|
FORBES-TATE | $80,000 reported |
|
2nd Quarter - Report 2nd Quarter 2020
|
FORBES-TATE | $60,000 reported |
|
Registration 2nd Quarter 2020
|
FORBES-TATE | — reported |
Filed by
Each firm that has reported for this client, and the client itself where it lobbies in-house, with the reports filed and the amounts they disclose.
| Firm | Reports | Amount |
|---|---|---|
| FORBES-TATE | 4 | $170,000 |
Issues lobbied
How many report sections named each issue, counting the current version of each report.
| Issue | Code | Mentions |
|---|---|---|
| Health Issues | HCR | 4 |
| Budget/Appropriations | BUD | 2 |
Bills named in its filings
Bill numbers found in the filers' descriptions, most often named first.
| Bill | Congress | Times named |
|---|---|---|
| H.R. 925 | 116th | 2 |
From reports filed under the Lobbying Disclosure Act. Firms report what each client paid them; an organisation lobbying for itself reports its own expenses. Amounts count the current version of each report once.